NOVAVAX INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.1B | $682.2M | $983.7M | $2.0B | $1.1B |
| Cost of revenue | $73.0M | $202.7M | $343.8M | $902.6M | $0 |
| Selling, general & administrative | $157.5M | $337.2M | $468.9M | $488.7M | — |
| Research and development | $342.3M | $391.2M | $737.5M | $1.2B | $2.5B |
| Operating income | $452.8M | -$248.9M | -$566.5M | -$644.7M | -$1.7B |
| Interest expense | $22.5M | $20.1M | $14.4M | $19.9M | $21.1M |
| Pretax income | $442.2M | -$176.6M | -$543.0M | -$653.6M | -$1.7B |
| Income tax expense | $1.9M | $10.9M | $2.0M | $4.3M | $29.2M |
| Net income | $440.3M | -$187.5M | -$545.1M | -$657.9M | -$1.7B |
| Balance Sheet | |||||
| Cash and equivalents | $240.6M | $530.2M | $568.5M | $1.3B | $1.5B |
| Current assets | $978.3M | $1.1B | $1.1B | $1.7B | $2.2B |
| Total assets | $1.2B | $1.6B | $1.8B | $2.3B | $2.6B |
| Current liabilities | $459.9M | $1.2B | $1.6B | $2.5B | $2.4B |
| Total liabilities | $1.3B | $2.2B | $2.5B | $2.9B | $2.9B |
| Stockholders' equity | -$127.8M | -$623.8M | -$716.9M | -$634.1M | -$351.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$244.6M | -$87.3M | -$714.0M | -$415.9M | $322.9M |
| Depreciation and amortization | $28.0M | $48.0M | $41.0M | $29.0M | $13.0M |
| Stock-based compensation | $36.0M | $48.2M | $85.4M | $130.3M | $183.6M |
| Capital expenditure | $0 | $1.1M | $7.9M | $17.7M | $57.5M |
| Free cash flow | -$244.6M | -$88.3M | -$721.9M | -$433.6M | $265.5M |
| Impairments | $0 | $4.1M | $10.1M | $0 | $0 |
Shares outstanding 164.4M · Free float 77.9%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.